• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

KemPharm touts efficacy data for pediatric ADHD therapy

July 9, 2018 By Sarah Faulkner

KemPharmKemPharm (NSDQ:KMPH) touted top-line data from a pivotal efficacy and safety trial of its KP415 pediatric ADHD product.

The company reported that KP415, which consists of serdexmethylphenidate and d-methylphenidate, met the primary efficacy endpoint in people with attention-deficit/hyperactivity disorder between the ages of 6 and 12 years.

KemPharm’s KP415 capsule makes use of d-MPH hydrochloride as an immediate release therapy and serdexmethylphenidate (a prodrug of d-MPH) as an extended-duration therapy. In the 150-person trial, participants received daily oral doses of either 28/6 mg SDX/d-MPH, 42/9 mg SDX/d-MPH or 56/12 mg SDX/d-MPH, corresponding to equivalent d-MPH amounts of 20, 30 and 40 mg, according to KemPharm.

Researchers optimized the dose of KP415 during a 3-week open-label phase of the trial. From there, participants were randomized to seven days of double-blind treatment with their optimized dose of KP415 or placebo.

“We are pleased with these top-line results from our pivotal trial of KP415.  The trial met its pre-specified primary endpoint, which is the mean difference in the SKAMP-Combined score change from baseline across all post-dose time points,” KemPharm president & CEO Travis Mickle said in prepared remarks.

“We anticipate developing additional clinical data for KP415 throughout 2018, including the completion of our ongoing oral and intranasal Human Abuse Potential studies,” Mickle added. “We believe that completing the analysis of the full data set from KP415.E01 trial and these other studies will allow us to submit our New Drug Application for KP415 with the FDA in the first quarter of 2019.”

KMPH shares were trading at $6.65 apiece in premarket activity at the time of publication, down -1.5%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: kempharm

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS